The gene-editing drug developer has completed its first publicly announced round to advance UC and ETH Zürich research.
Spotlight Therapeutics, a US-based gene therapy developer advancing University of California (UC) and ETH Zürich research, has raised $30m in a series A round led by GV, a corporate venturing subsidiary of conglomerate Alphabet.
The corporate was joined by undisclosed other investors, the round coming in the wake of $7.3m in equity funding in January 2018 and $6.9m in September 2019, according to regulatory filings.
Spotlight is working on cell-targeted therapeutics for cancer and a class of blood disorders known as hemoglobinopathies. They will utilise Crispr gene editing technology and are being developed through its Targeted Active Gene Editor (TAGE) platform.
The company is advancing research by scientific co-founders Alex Marson, an associate professor at UC San Francisco, Patrick Hsu, an assistant professor at UC Berkeley, and Prof Jacbo Horn at ETH Zürich.
Marson said: “Spotlight’s unique approach represents the potential to expand applications and democratise…
